MAIA Biotechnology Reveals Promising Phase 2 Trial Results
Company Announcements

MAIA Biotechnology Reveals Promising Phase 2 Trial Results

MAIA Biotechnology, Inc. ( (MAIA) ) has provided an update.

MAIA Biotechnology has unveiled promising new data from its Phase 2 trial of THIO combined with cemiplimab, showing significant survival benefits for advanced lung cancer patients who have exhausted other treatments. Highlights include median survival follow-ups of over 11 months for third-line treatments. The findings, presented at the SITC Annual Meeting, underscore the potential of THIO in enhancing cancer treatment outcomes. Investors should note these forward-looking statements are subject to uncertainties and risks.

See more insights into MAIA stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMAIA Biotechnology Advances with Clinical Trials and Partnerships
TheFlyMAIA Biotechnology’s THIO shows positive survival data in lung cancer study
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App